Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Ca

DelveInsight's "Gastroenteropancreatic Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastroenteropancreatic Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroenteropancreatic Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroenteropancreatic Neuroendocrine Tumor Market Forecast
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Gastroenteropancreatic Neuroendocrine Tumor Market Report:
• The Gastroenteropancreatic Neuroendocrine Tumor market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In September 2023, The primary endpoint of the Phase III NETTER-2 trial including Lutathera® (USAN: lutetium Lu 177 dotatate; INN: lutetium (177Lu) oxodotreotide) was achieved, according to Novartis. When compared to high-dose long-acting octreotide alone, first-line treatment with Lutathera in conjunction with long-acting octreotide significantly improved the progression-free survival (PFS) for patients with newly diagnosed somatostatin receptor (SSTR)-positive, Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs1),2. The study yielded no unexpected or novel safety results, and the data are in line with the well-established safety profile of lutethera.
• According to Masui et al. (2020), Japan had an age-adjusted overall incidence of 3.53 per 100,000 for gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN). While the majority of NENs in the duodenum, ileum, appendix, and rectm were grade 1 neuroendocrine tumors (NETs), the majority of NENs in the esophagus or lungs were neuroendocrine carcinomas (NECs).
• Among the 15,222 NET cases diagnosed between 2013 and 2015, according to Genus et al. (2019), 50,7% had GEP-NENs; this patient cohort comprised both NETs and NECs, with the latter accounting for 37% of all cases
• Of the 837 GEP NETcases identified in Spain between 2001 and 2008, 1.7% were classified as poorly differentiated tumors, according to Garcia-Carbonero et al. (2010). The percentage of cases with probable gastrointestinal origin net tumors that were small intestinal, pancreatic, and unknown primary were, respectively, 55%, 36.3%, and 9.1%
• Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others
• Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others
• The Gastroenteropancreatic Neuroendocrine Tumor epidemiology based on gender analyzed that the incidence of functional GEP-NET is more than that of nonfunctional GEP-NET in the United States
• The Gastroenteropancreatic Neuroendocrine Tumor market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroenteropancreatic Neuroendocrine Tumor pipeline products will significantly revolutionize the Gastroenteropancreatic Neuroendocrine Tumor market dynamics.

Gastroenteropancreatic Neuroendocrine Tumor Overview
Tumors that originate from the gut's neuroendocrine cells are known as gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. Hormones that regulate the digestive system's numerous processes are released by these cells. The location of the tumor in the gut and whether it is producing too many hormones determine the symptoms of GEP-NETs. The malignancies had already migrated to other organs, including the liver, by the time of diagnosis.

Get a Free sample for the Gastroenteropancreatic Neuroendocrine Tumor Market Report
https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Segmentation:
The Gastroenteropancreatic Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Gastroenteropancreatic Neuroendocrine Tumor
• Prevalent Cases of Gastroenteropancreatic Neuroendocrine Tumor by severity
• Gender-specific Prevalence of Gastroenteropancreatic Neuroendocrine Tumor
• Diagnosed Cases of Episodic and Chronic Gastroenteropancreatic Neuroendocrine Tumor

Download the report to understand which factors are driving Gastroenteropancreatic Neuroendocrine Tumor epidemiology trends @ Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Forecast
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroenteropancreatic Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroenteropancreatic Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Gastroenteropancreatic Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastroenteropancreatic Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroenteropancreatic Neuroendocrine Tumor Therapies and Key Companies
• ITM-11: ITM Isotope Technologies Munich
• CAM2029: Camurus
• RYZ101: RayzeBio
• Lanreotide: Merck Sharp & Dohme
• arginine/lysine: Advanced Accelerator
• Temozolomide (TMZ): Ipsen
• Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine
• RYZ101: RayzeBio, Inc.
• CAM2029: Camurus AB
• Everolimus: Novartis
• PEN-221: Tarveda Therapeutics
• Lutathera: Progenics Pharmaceuticals
• Ibrutinib: Pharmacyclics

Discover more about therapies set to grab major Gastroenteropancreatic Neuroendocrine Tumor market share @ Gastroenteropancreatic Neuroendocrine Tumor Treatment Market
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Gastroenteropancreatic Neuroendocrine Tumor Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others
• Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others
• Gastroenteropancreatic Neuroendocrine Tumor Therapeutic Assessment: Gastroenteropancreatic Neuroendocrine Tumor current marketed and Gastroenteropancreatic Neuroendocrine Tumor emerging therapies
• Gastroenteropancreatic Neuroendocrine Tumor Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumor market drivers and Gastroenteropancreatic Neuroendocrine Tumor market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs, KOL's views, Analyst's views, Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement

To know more about Gastroenteropancreatic Neuroendocrine Tumor companies working in the treatment market, visit @ Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Gastroenteropancreatic Neuroendocrine Tumor Market Report Introduction
2. Executive Summary for Gastroenteropancreatic Neuroendocrine Tumor
3. SWOT analysis of Gastroenteropancreatic Neuroendocrine Tumor
4. Gastroenteropancreatic Neuroendocrine Tumor Patient Share (%) Overview at a Glance
5. Gastroenteropancreatic Neuroendocrine Tumor Market Overview at a Glance
6. Gastroenteropancreatic Neuroendocrine Tumor Disease Background and Overview
7. Gastroenteropancreatic Neuroendocrine Tumor Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastroenteropancreatic Neuroendocrine Tumor
9. Gastroenteropancreatic Neuroendocrine Tumor Current Treatment and Medical Practices
10. Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs
11. Gastroenteropancreatic Neuroendocrine Tumor Emerging Therapies
12. Gastroenteropancreatic Neuroendocrine Tumor Market Outlook
13. Country-Wise Gastroenteropancreatic Neuroendocrine Tumor Market Analysis (2019-2032)
14. Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement of Therapies
15. Gastroenteropancreatic Neuroendocrine Tumor Market Drivers
16. Gastroenteropancreatic Neuroendocrine Tumor Market Barriers
17. Gastroenteropancreatic Neuroendocrine Tumor Appendix
18. Gastroenteropancreatic Neuroendocrine Tumor Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Gastroenteropancreatic Neuroendocrine Tumor Pipeline https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Gastroenteropancreatic Neuroendocrine Tumor Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Gastroenteropancreatic Neuroendocrine Tumor market. A detailed picture of the Gastroenteropancreatic Neuroendocrine Tumor pipeline landscape is provided, which includes the disease overview and Gastroenteropancreatic Neuroendocrine Tumor treatment guidelines.
Gastroenteropancreatic Neuroendocrine Tumor Epidemiology https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Gastroenteropancreatic Neuroendocrine Tumor epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Chronic Constipation Market https://www.delveinsight.com/report-store/chronic-constipation-market
DelveInsight's "Chronic Constipation Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Constipation, historical and forecasted epidemiology as well as the Chronic Constipation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fungal pneumonia Market
https://www.delveinsight.com/report-store/fungal-pneumonia-market
DelveInsight's "Fungal Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Fungal Pneumonia, historical and forecasted epidemiology as well as the Fungal Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Spinal Muscular Atrophy Market
https://www.delveinsight.com/report-store/spinal-muscular-atrophy-market
DelveInsight's "Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Spinal Muscular Atrophy, historical and forecasted epidemiology as well as the Spinal Muscular Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market
DelveInsight's "Morquio Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Morquio Syndrome, historical and forecasted epidemiology as well as the Morquio Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Diabetic neuropathy Market
https://www.delveinsight.com/report-store/diabetic-neuropathy-market
DelveInsight's "Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Diabetic Neuropathy, historical and forecasted epidemiology as well as the Diabetic Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.